IR 902 - Immune Response BioPharma
Alternative Names: AI 208; IR-208; Multiple sclerosis vaccine - Immune Response BioPharma; NeuroVax; V beta 17Latest Information Update: 26 Apr 2022
At a glance
- Originator Immune Response Corporation
- Developer Immune Response BioPharma; Orchestra Therapeutics
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Multiple sclerosis
Highest Development Phases
- Phase II/III Multiple sclerosis
Most Recent Events
- 26 Apr 2022 Phase II/III development is still ongoing for Multiple sclerosis in USA (IM) (NCT02057159)
- 09 Mar 2020 Phase-II/III clinical trials in Multiple sclerosis in USA (IM) (NCT02057159)
- 09 Jul 2019 IR 902 is still in phase II trial for Multiple sclerosis in USA (NDR batch #16)